CAPR stock rises nearly 5% as Capricor presents Deramiocel data
Capricor Therapeutics’ CAPR shares rose about 5% after the company presented clinical heart data for Deramiocel in Duchenne muscular dystrophy ahead of an anticipated November FDA decision.
Shares of Capricor Therapeutics rose 5% on Wednesday after the company presented clinical data from trials of its experimental cell therapy Deramiocel for Duchenne muscular dystrophy. The data included stabilization of heart function in boys who already had heart damage, alongside previously annou…